免疫抑制剂的中国专利文献计量分析

Chinese Patent Bibliometric Analysis of Immunosuppressants

目的探讨国内有关免疫抑制剂的专利申请状况和研发趋势。方法采用文献计量学的方法,通过在专利数据库中检索相关专利文献,对专利申请的法律状态、时间、区域、申请人、技术热点等方面的分布情况进行研究分析。结果与结论国内免疫抑制剂相关专利的数量自2005年起呈逐年上升的趋势;截止2017年8月有效专利的比例为27.95%;且专利集中程度高,全球专利多集中在日本、澳大利亚、加拿大等发达国家,国内的专利申请中也不乏外国企业;国内医药企业的申请量和研发实力与美日欧等发达国家仍有差距;目前免疫抑制剂专利技术热点主要集中在杂环化合物和肽类物质,以及免疫球蛋白类药物。国内医药企业可以考虑产学研合作,并重视对失效专利的挖掘和再利用,以提升研发实力,获取更多的研发成果。

OBJECTIVE To explore the status of patent applications and research and development trends in immunosuppressants. METHODS Using the method of bibliometrics, the patent application in terms of legal status, time, region, applicant and technical hotspotby retrieving the relevant patent literatures from the patent database were analyzed. RESULTS CONCLUSION The number of patents regards to domestic immunosuppressants had been increasing year by year since 2005. By August 2017 the proportion of effective patents reached to 27.95%. Most of the global patents were concentrated in Japan, Australia, Canada and other developed countries, domestic patent applications were also lacking in foreign enterprises; there was a significant gap between domestic pharmaceutical companies and the United States and Japan or other developed countries in the quantities of patent applications as well as RD competence. At present, immunosuppressants patented technology focuses mainly on heterocyclic compounds and peptides, and immunoglobulin drugs. Perhaps domestic pharmaceutical companies could consider the opportunity to collaborate with them in Industry-University-Research, and take account of invalid patents which could have the potential to be reused. In this way, they could improve their research ability and acquire further outcome.